Literature DB >> 22477648

Cardiovascular risk management of hypertension and hypercholesterolaemia in the Netherlands: from unifactorial to multifactorial approach.

I van Dis1, J M Geleijnse, W M M Verschuren, D Kromhout.   

Abstract

About 30 years ago, the first Dutch unifactorial guidelines on hypertension and hypercholesterolaemia were developed. These guidelines have been revised several times, often after publication of landmark studies on new generations of drugs. In 1978, cut-off points for pharmacological treatment of hypertension were based on diastolic blood pressure values ≥115 mmHg, and in 2000 they were lowered to >100 mmHg. From 1997 onwards, cut-off points for systolic blood pressure values >180 mmHg were introduced, which became leading. In 1987, cut-offs for hypercholesterolaemia of ≥8 mmol/l were set and from 2006 pharmacological treatment was based on a total/HDL cholesterol ratio >8. Around 2000, treatment decisions for hypertension and/or hypercholesterolaemia were no longer based on high levels of individual risk factors, but on a multifactorial approach based on total risk of cardiovascular diseases (CVD), determined by a risk function. In the 2006 multidisciplinary guideline on cardiovascular risk management, the Framingham risk tables were replaced by European SCORE risk charts. A cut-off point of 10% CVD mortality was set in the Netherlands. In 2011, this cut-off point changed to 20% fatal plus nonfatal CVD risk. Nowadays, 'the lower the risk factors, the lower the absolute risk' is the leading paradigm in CVD prevention.

Entities:  

Year:  2012        PMID: 22477648      PMCID: PMC3402568          DOI: 10.1007/s12471-012-0268-8

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  24 in total

1.  European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).

Authors:  Ian Graham; Dan Atar; Knut Borch-Johnsen; Gudrun Boysen; Gunilla Burell; Renata Cifkova; Jean Dallongeville; Guy De Backer; Shah Ebrahim; Bjørn Gjelsvik; Christoph Herrmann-Lingen; Arno Hoes; Steve Humphries; Mike Knapton; Joep Perk; Silvia G Priori; Kalevi Pyorala; Zeljko Reiner; Luis Ruilope; Susana Sans-Menendez; Wilma Scholte Op Reimer; Peter Weissberg; David Wood; John Yarnell; Jose Luis Zamorano; Edmond Walma; Tony Fitzgerald; Marie Therese Cooney; Alexandra Dudina; Alec Vahanian; John Camm; Raffaele De Caterina; Veronica Dean; Kenneth Dickstein; Christian Funck-Brentano; Gerasimos Filippatos; Irene Hellemans; Steen Dalby Kristensen; Keith McGregor; Udo Sechtem; Sigmund Silber; Michal Tendera; Petr Widimsky; Jóse Luis Zamorano; Attila Altiner; Enzo Bonora; Paul N Durrington; Robert Fagard; Simona Giampaoli; Harry Hemingway; Jan Hakansson; Sverre Erik Kjeldsen; mogens Lytken Larsen; Giuseppe Mancia; Athanasios J Manolis; Kristina Orth-Gomer; Terje Pedersen; Mike Rayner; Lars Ryden; Mario Sammut; Neil Schneiderman; Anton F Stalenhoef; Lale Tokgözoglu; Olov Wiklund; Antonis Zampelas
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2007-09

2.  An updated coronary risk profile. A statement for health professionals.

Authors:  K M Anderson; P W Wilson; P M Odell; W B Kannel
Journal:  Circulation       Date:  1991-01       Impact factor: 29.690

3.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

4.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

5.  Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group.

Authors: 
Journal:  JAMA       Date:  1979-12-07       Impact factor: 56.272

Review 6.  The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials.

Authors:  J J Brugts; T Yetgin; S E Hoeks; A M Gotto; J Shepherd; R G J Westendorp; A J M de Craen; R H Knopp; H Nakamura; P Ridker; R van Domburg; J W Deckers
Journal:  BMJ       Date:  2009-06-30

Review 7.  Hypertension in the elderly. Implications and generalizability of randomized trials.

Authors:  C D Mulrow; J A Cornell; C R Herrera; A Kadri; L Farnett; C Aguilar
Journal:  JAMA       Date:  1994-12-28       Impact factor: 56.272

Review 8.  Treating mild hypertension. Report of the British Hypertension Society working party.

Authors: 
Journal:  BMJ       Date:  1989-03-18

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

Review 10.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.

Authors:  M R Law; J K Morris; N J Wald
Journal:  BMJ       Date:  2009-05-19
View more
  7 in total

1.  Should non-cardiovascular mortality be considered in the SCORE model? Findings from the Prevention of Renal and Vascular End-stage Disease (PREVEND) cohort.

Authors:  Biniyam G Demissei; Douwe Postmus; Mattia A Valente; Pim van der Harst; Wijk H van Gilst; Edwin R Van den Heuvel; Hans L Hillege
Journal:  Eur J Epidemiol       Date:  2014-11-07       Impact factor: 8.082

2.  CVON: a laudable strategy waiting for societal impact.

Authors:  E E van der Wall
Journal:  Neth Heart J       Date:  2015-04       Impact factor: 2.380

3.  Mortality decrease from cardiovascular disease in Europe: 50 % in 30 years!

Authors:  E E van der Wall
Journal:  Neth Heart J       Date:  2013-10       Impact factor: 2.380

4.  Effects of long-term magnesium supplementation on endothelial function and cardiometabolic risk markers: A randomized controlled trial in overweight/obese adults.

Authors:  Peter J Joris; Jogchum Plat; Stephan J L Bakker; Ronald P Mensink
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

5.  Hypercholesterolaemia: optimal treatment by next-generation drugs?

Authors:  E E van der Wall
Journal:  Neth Heart J       Date:  2015-09       Impact factor: 2.380

6.  Prevalence of psychological distress in elderly hypertension patients in primary care.

Authors:  L Ringoir; S S Pedersen; J W M G Widdershoven; V J M Pop
Journal:  Neth Heart J       Date:  2014-02       Impact factor: 2.380

7.  Heart disease in the Netherlands: a quantitative update.

Authors:  M J G Leening; S Siregar; I Vaartjes; M L Bots; M I M Versteegh; R-J M van Geuns; J J Koolen; J W Deckers
Journal:  Neth Heart J       Date:  2014-01       Impact factor: 2.380

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.